Transforming how the world collaborates on originating, assessing, and advancing critical science, technology, and infrastructure
TAP is an AI-native company with High Performance Compute (HPC) capabilities. We form, orchestrate, and connect distributed innovation systems with a focus on compounding knowledge, spanning life sciences, materials science, healthcare, quantum, operations, and finance. These collaborations operate across structures, organizations, disciplines, geographies, and datasets through partnerships that bring critical innovation to market faster and more efficiently.
Our system is built from the ground up as AI-native, orchestrating intelligent networks across deep tech domains. With state-of-the-art architectures for pattern recognition, optimization, and multi-modal learning across physical, digital, and computational spaces, this introduces breakthrough opportunities through mitigating non-scientific barriers to innovation, especially coordination problems.
Each collaboration teaches the network how to form better connections, transforming deep technology development into a continuously improving, distributed intelligence. The system doesn't just learn about specific technologies—it learns how to optimize the innovation process itself across domains.
Every result across deep tech domains feeds back into AI models, creating a continuous learning loop that improves predictive accuracy across the entire network. Through rapid empirical validation of computational predictions, results immediately inform model refinement and next-round predictions. This iterative refinement creates compounding system intelligence while providing embedded risk management, with orchestration capturing and pushing feedback to other nodes, improving learning with each cycle and resulting in greater scope for value creation.
We operate dynamic portfolios across multiple deep tech domains, continuously optimizing through our purge-pause-promote framework. Our portfolio decisions are data enabled, using this framework to end candidates that underperform, pause promising candidates unready at time of evaluation, and prioritize candidates with future facing resilience. Paused candidates can be revisited as conditions evolve. The aim is to eliminate and pause early, preferably pre-formation, creating more scope for breakthroughs at the portfolio level.
Parallel processing across our network accelerates deep tech development timelines. Our learn-fast approach enables rapid decision-making and program advancement across domains, with continuous flow from concept through development guided by empirical loops and computational predictions. Using simulations and empirical loops to catch false positives early gives us more opportunities to succeed while removing obstacles to high-risk high-potential ideas.
Commercially viable companies or IP are spun out through focused initiatives. Capital recycles into the Holdco through distributions, portfolio licensing, portfolio exits or portfolio IPOs, while new spin-outs are dynamically created as opportunities emerge across the deep tech landscape.
Special Assistant to the President, Biological Threats • Managing Director/Partner, BCG, PwC • Operation Warp Speed architect
Corporate and Technology Strategy • Entrepreneur, Co-Founder ValueAI Institute • Investor, Venture Partner
Senior Pharma Leadership • AI-driven Drug Discovery, Portfolio • Platform Technology and Science, GSK
Machine Learning, Deep Learning • AI Researcher/Instructor, Berkeley, NASA • Founder, Silicon Valley Bank AI Lab
Head of Operations, SaponiQx • Novavax Vaccine Lead, US Government Operation Warp Speed • Technology Selection and Clinical Evaluation, Department of Defense
Medicinal Chemist • Director, Exelixis • Principal Scientist, Merck
Machine Learning, Computational Biology, Cancer Genomics • CSO / CTO, Cancer IQ
Quantum Computing • Senior Engineer, IonQ • Machine Learning & Physics • Financial Industry Quant
Physician Executive & Software Engineer • Chief Medical Officer, United Healthcare, VA • Faculty, Harvard Medical School • Health Tech Turnaround Leader
Medical Strategy • CMO, ADC Therapeutics • SVP, Celgene, Pfizer, Wyeth
DNA Encoded Libraries • Informatics & Molecular Biology, Dice Therapeutics
Management Systems • High Performance Organization • Senior Lecturer, MIT Sloan
Life Sciences Strategy & Business Operations • Supply Chain, Project Management • Boston Consulting Group
Senior Pharma Leadership • Collaborative Drug Discovery, InnoCentive • R&D Executive, Eli Lilly
Founder • Distributed Innovation • Entrepreneur, Impact Investor
TAP engages with partners by referral.